<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mgimolaw</journal-id><journal-title-group><journal-title xml:lang="ru">Московский журнал международного права</journal-title><trans-title-group xml:lang="en"><trans-title>Moscow Journal of International Law</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0869-0049</issn><issn pub-type="epub">2619-0893</issn><publisher><publisher-name>Moscow State Institute of International Relations</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24833/0869-0049-2014-2-4-20</article-id><article-id custom-type="elpub" pub-id-type="custom">mgimolaw-18</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРАВА ЧЕЛОВЕКА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>HUMAN RIGHTS</subject></subj-group></article-categories><title-group><article-title>Проблемы международно-правовой квалификации нарушений прав человека фармацевтическими компаниями</article-title><trans-title-group xml:lang="en"><trans-title>The International Legal Responsibility of Pharmaceutical Companies for Human Rights Violations</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абашидзе</surname><given-names>Аслан Хусейнович</given-names></name><name name-style="western" xml:lang="en"><surname>Abashidze</surname><given-names>Aslan H.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маличенко</surname><given-names>Владислав Сергеевич</given-names></name><name name-style="western" xml:lang="en"><surname>Malichenko</surname><given-names>Vladislav S.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>РУДН</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Peoples’ Friendship University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>МГИМО (У) МИД России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>MGIMO-University MFA Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>30</day><month>06</month><year>2014</year></pub-date><volume>2</volume><issue>2</issue><fpage>4</fpage><lpage>20</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Абашидзе А.Х., Маличенко В.С., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Абашидзе А.Х., Маличенко В.С.</copyright-holder><copyright-holder xml:lang="en">Abashidze A.H., Malichenko V.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mjil.ru/jour/article/view/18">https://www.mjil.ru/jour/article/view/18</self-uri><abstract><p>Фармацевтический сектор играет важную роль в обеспечении права человека на здоровье путем создания условий для доступа к лекарственным средствам. Однако, политика и практика крупных фармацевтических компаний создает государствам дополнительные проблемы в реализации права людей на наивысший достижимый уровень здоровья, в результате затрудняются их усилия по обеспечению доступа к лекарственным средствам. В современном международном праве фактически отсутствуют положения, позволяющие привлекать фармацевтические компании к ответственности за нарушения прав человека. Вместе с тем в условиях роста количества нарушений прав человека со стороны фармацевтических компаний и отсутствия эффективных национально-правовых средств правовой защиты, все более очевидной становится необходимость в действенном международном механизме привлечения фармацевтических компаний к ответственности за нарушения прав человека, учитывающего накопленный национальный опыт в данной области.</p></abstract><trans-abstract xml:lang="en"><p>The pharmaceutical sector plays an important role in ensuring the right to health by creating conditions for access to medicines. However, the policy and practice of a number of big pharmaceutical companies creates additional problems for the States in realisation of citizens’ rights to the highest attainable standard of health and as a result interferes with their efforts to ensure access to medicines. In contemporary international law there are virtually no provisions allowing making pharmaceutical companies accountable for human rights violations. However, in a growing number of human rights violations on the part of pharmaceutical companies and the lack of effective national legal remedies, the need of an effective international mechanism, which will take into account the national experience acquired in this fi eld and make pharmaceutical companies accountable for violations of human rights, becomes increasingly apparent.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>фармацевтические компании</kwd><kwd>ответственность</kwd><kwd>права человека на здоровье</kwd><kwd>лекарственные средства</kwd><kwd>монополия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pharmaceutical companies</kwd><kwd>responsibility</kwd><kwd>the right to health</kwd><kwd>medicines</kwd><kwd>monopoly</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Маличенко В.С. Обращение лекарственных средств - элемент стратегии национальной безопасности США Обозреватель №7, 2013 стр. 80-91</mixed-citation><mixed-citation xml:lang="en">Маличенко В.С. Обращение лекарственных средств - элемент стратегии национальной безопасности США Обозреватель №7, 2013 стр. 80-91</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">J.A.Dimassi, “The price of innovation: New estimates of drug development Costs”, Journal of Health Economics 22 №2, March 2003: p. 151-185.</mixed-citation><mixed-citation xml:lang="en">J.A.Dimassi, “The price of innovation: New estimates of drug development Costs”, Journal of Health Economics 22 №2, March 2003: p. 151-185.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">J. Love, “IRS Data Shows Drug Industry Cost Estimates Exaggerated,” Knowledge Economy International news release, Washington D.C, November 30, 2001.</mixed-citation><mixed-citation xml:lang="en">J. Love, “IRS Data Shows Drug Industry Cost Estimates Exaggerated,” Knowledge Economy International news release, Washington D.C, November 30, 2001.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">G.Foster, “Opposing Forces in s Revolution in International Patent Protection: The U.S. and India in the Uruguay Round and its Aftermath” UCLA Journal of International Law and Foreign Affairs.</mixed-citation><mixed-citation xml:lang="en">G.Foster, “Opposing Forces in s Revolution in International Patent Protection: The U.S. and India in the Uruguay Round and its Aftermath” UCLA Journal of International Law and Foreign Affairs.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Leaf С., «The Law of Unintended Consequences», Fortune, September 19, 2005.</mixed-citation><mixed-citation xml:lang="en">Leaf С., «The Law of Unintended Consequences», Fortune, September 19, 2005.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Goozner M. The $800 million pill: the truth behind the cost of new drugs. Berkley: University of California Press; Press 2005.</mixed-citation><mixed-citation xml:lang="en">Goozner M. The $800 million pill: the truth behind the cost of new drugs. Berkley: University of California Press; Press 2005.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Stevens A.J., Jensen J.J., Wyller K, et al. The role of public-sector research in the discovery of drugs and vaccines. New England Journal of Medicine. 2011; 364: 535-41.</mixed-citation><mixed-citation xml:lang="en">Stevens A.J., Jensen J.J., Wyller K, et al. The role of public-sector research in the discovery of drugs and vaccines. New England Journal of Medicine. 2011; 364: 535-41.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Boseley S. Scandal of scientists who take money for papers ghostwritten by the drug companies. The Guardian. 2002. Feb 7.</mixed-citation><mixed-citation xml:lang="en">Boseley S. Scandal of scientists who take money for papers ghostwritten by the drug companies. The Guardian. 2002. Feb 7.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ross D.B. The FDA and the case of Ketek. New England Journal of Medicine.2007; 356: 1675-6.</mixed-citation><mixed-citation xml:lang="en">Ross D.B. The FDA and the case of Ketek. New England Journal of Medicine.2007; 356: 1675-6.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Day M. Italian police arrest drug ofﬁ cials over alleged falsiﬁ cation on data. BMJ. 2008; 336: 1208-9.</mixed-citation><mixed-citation xml:lang="en">Day M. Italian police arrest drug ofﬁ cials over alleged falsiﬁ cation on data. BMJ. 2008; 336: 1208-9.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lurie P., Wolfe S.M. FDA medical ofﬁ cers report lower standards permit dangerous drug approvals. Public citizen. 1998.</mixed-citation><mixed-citation xml:lang="en">Lurie P., Wolfe S.M. FDA medical ofﬁ cers report lower standards permit dangerous drug approvals. Public citizen. 1998.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Willman D. Diabetes Drug rezulin pulled off the market. Los Angeles Times. March. 2000.</mixed-citation><mixed-citation xml:lang="en">Willman D. Diabetes Drug rezulin pulled off the market. Los Angeles Times. March. 2000.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bailey R.S. FDA corruption charges letter veriﬁ ed. The Los Angeles Post. 2012 April 8.</mixed-citation><mixed-citation xml:lang="en">Bailey R.S. FDA corruption charges letter veriﬁ ed. The Los Angeles Post. 2012 April 8.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Xi.Yu. Three Professors face sanctions following Harvard medical school inquiry. Harvard crimson. 2011.</mixed-citation><mixed-citation xml:lang="en">Xi.Yu. Three Professors face sanctions following Harvard medical school inquiry. Harvard crimson. 2011.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Special Rapporteur of the Commission on Human Rights on the Right to the Enjoyment of the Highest Attainable Standard on Physical and Mental Health. UN Doc. A/HRC/11/12/ ADD.2 (2009).</mixed-citation><mixed-citation xml:lang="en">Special Rapporteur of the Commission on Human Rights on the Right to the Enjoyment of the Highest Attainable Standard on Physical and Mental Health. UN Doc. A/HRC/11/12/ ADD.2 (2009).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Абашидзе А.Х., Маличенко В.С. Обеспечение доступа к лекарственным средствам в условиях развития механизмов защиты прав интеллектуальной собственности. Современное право №7. 2013. Cтр. 155-157.</mixed-citation><mixed-citation xml:lang="en">Абашидзе А.Х., Маличенко В.С. Обеспечение доступа к лекарственным средствам в условиях развития механизмов защиты прав интеллектуальной собственности. Современное право №7. 2013. Cтр. 155-157.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">G.Harris «Prilosec’s Maler Switches Users to Nexium, Thwarting Generics», Wall street Journal, June 6, 2002</mixed-citation><mixed-citation xml:lang="en">G.Harris «Prilosec’s Maler Switches Users to Nexium, Thwarting Generics», Wall street Journal, June 6, 2002</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Rost P. The Whistleblower: confessions of a healthcare hitman. New York: Soft skull press. 2006.</mixed-citation><mixed-citation xml:lang="en">Rost P. The Whistleblower: confessions of a healthcare hitman. New York: Soft skull press. 2006.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Rockoff J.D., Matthews C.M. Pﬁ zer settles federal bribery investigation. Wall street journal. 2012 Aug 7.</mixed-citation><mixed-citation xml:lang="en">Rockoff J.D., Matthews C.M. Pﬁ zer settles federal bribery investigation. Wall street journal. 2012 Aug 7.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kelton E. J&amp;J needs a cure: new CEO allegedly had links to fraud. Forbes 2012 19 April</mixed-citation><mixed-citation xml:lang="en">Kelton E. J&amp;J needs a cure: new CEO allegedly had links to fraud. Forbes 2012 19 April</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">http://www1.umn.edu/humanrts/russian/links/Rnorms-Aug2003.html.</mixed-citation><mixed-citation xml:lang="en">http://www1.umn.edu/humanrts/russian/links/Rnorms-Aug2003.html.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
